KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $389.4 million.

  • Vertex Pharmaceuticals' Gains from Investment Securities rose 4326.71% to $389.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 20956.33%. This contributed to the annual value of $1.6 billion for FY2025, which is 4478.33% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Gains from Investment Securities of $389.4 million as of Q4 2025, which was up 4326.71% from $479.6 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Gains from Investment Securities high stood at $758.2 million for Q4 2023, and its period low was -$49.2 million during Q2 2022.
  • Its 5-year average for Gains from Investment Securities is $174.1 million, with a median of $109.8 million in 2021.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Gains from Investment Securities plummeted by 317500.0% in 2022 and then skyrocketed by 15976666.67% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Gains from Investment Securities stood at $94.8 million in 2021, then surged by 129.64% to $217.7 million in 2022, then skyrocketed by 248.28% to $758.2 million in 2023, then crashed by 64.15% to $271.8 million in 2024, then skyrocketed by 43.27% to $389.4 million in 2025.
  • Its last three reported values are $389.4 million in Q4 2025, $479.6 million for Q3 2025, and $427.2 million during Q2 2025.